SCHEMBL831048

SCHEMBL831048

CCc1nc(-c2ccc(Cl)cc2)cc(CC(C)C)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.46
FABP4 P15090 1/20 0.46
FABP5 Q01469 1/20 0.46
CTRC Q99895 4/20 0.44
DHODH Q02127 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
CRHBP P24387 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
CRHR2 Q13324 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDE4A P27815 1/20 0.40
ADORA3 P0DMS8 2/20 0.40
DPP4 P27487 2/20 0.39
DPP8 Q6V1X1 2/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832260 0.89 DPP4 (0.50) CTRCDHODHSMN1; SMN2PDE4AADORA3
SCHEMBL831416 0.87 MAPT (0.43) CTRCLMNAALDH1A1HPGDMAPT
SCHEMBL829550 0.81 DHODH (0.36) FABP3FABP4FABP5DHODHLMNA
SCHEMBL830490 0.81 KMO (0.46) FABP3FABP4FABP5DHODHPDE4A
SCHEMBL833067 0.80 CNR2 (0.43) FABP3FABP4FABP5DHODHSMN1; SMN2
SCHEMBL831049 0.80 FABP3 (0.47) FABP3FABP4FABP5CTRCDHODH
SCHEMBL4007857 0.79 FABP3 (0.45) FABP3FABP4FABP5CTRCLMNA
SCHEMBL839964 0.77 FABP3 (0.49) FABP3FABP4FABP5CTRCDHODH
SCHEMBL830805 0.76 POLB (0.46) CTRCDHODHLMNAALDH1A1HPGD
SCHEMBL830293 0.76 ADORA3 (0.41) ALDH1A1MAPTKMT2ASMN1; SMN2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT FABP3 2/4885FABP4 183/4885FABP5 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.